Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more
Carisma Therapeutics Inc. (CARM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -2.201x
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has a cash flow conversion efficiency ratio of -2.201x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Million) by net assets ($-867.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Carisma Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Carisma Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carisma Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apogee Minerals Ltd
V:APMI
|
0.039x |
|
Shree Ram Proteins Limited
NSE:SRPL
|
0.071x |
|
Syra Health Corp. Class A Common Stock
NASDAQ:SYRA
|
-0.046x |
|
Stamper Oil & Gas Corp
PINK:STMGF
|
-0.082x |
|
ALTECH ADV.MAT. NA O.N.
F:AMA
|
N/A |
|
MOJ S.A
WAR:MOJ
|
0.054x |
|
QUALCOMM (QCI.SG)
STU:QCI
|
0.101x |
|
D R HORTON - Dusseldorf Stock Exchang
DU:HO2
|
0.028x |
Annual Cash Flow Conversion Efficiency for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-27.91 Million | $-59.92 Million | 2.147x | +170.17% |
| 2023-12-31 | $26.53 Million | $-81.18 Million | -3.060x | -5869.38% |
| 2022-12-31 | $-142.67 Million | $-7.57 Million | 0.053x | +124.39% |
| 2021-12-31 | $171.71 Million | $-37.33 Million | -0.217x | -107.43% |
| 2020-12-31 | $-9.23 Million | $-27.01 Million | 2.927x | +108.32% |
| 2019-12-31 | $-26.70 Million | $-37.52 Million | 1.405x | +372.12% |
| 2018-12-31 | $44.21 Million | $-22.83 Million | -0.516x | +47.58% |
| 2017-12-31 | $18.03 Million | $-17.77 Million | -0.985x | -1553.09% |
| 2016-12-31 | $38.68 Million | $2.62 Million | 0.068x | +103.72% |
| 2015-12-31 | $18.94 Million | $-34.53 Million | -1.823x | -129.03% |
| 2014-12-31 | $36.83 Million | $-29.31 Million | -0.796x | +86.16% |
| 2013-12-31 | $2.35 Million | $-13.49 Million | -5.752x | -72.90% |
| 2012-12-31 | $5.74 Million | $-19.09 Million | -3.327x | -104.50% |
| 2011-12-31 | $-147.00K | $-10.87 Million | 73.939x | -- |